The changing treatment landscape in idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and irreversible fibrotic disease of the lung that has greatly frustrated clinicians for a long time. The prognosis of IPF (median survival 2–5 years following diagnosis) is poorer than that of some cancers and for many years no significa...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2015-03-01
|
| Series: | European Respiratory Review |
| Online Access: | http://err.ersjournals.com/content/24/135/65.full.pdf+html |
| id |
doaj-18cb7be5f8c1465aa62be6a5c74f0d50 |
|---|---|
| record_format |
Article |
| spelling |
doaj-18cb7be5f8c1465aa62be6a5c74f0d502020-11-25T03:35:17ZengEuropean Respiratory SocietyEuropean Respiratory Review0905-91801600-06172015-03-0124135656810.1183/09059180.00011414The changing treatment landscape in idiopathic pulmonary fibrosisUlrich CostabelIdiopathic pulmonary fibrosis (IPF) is a chronic, progressive and irreversible fibrotic disease of the lung that has greatly frustrated clinicians for a long time. The prognosis of IPF (median survival 2–5 years following diagnosis) is poorer than that of some cancers and for many years no significant advances were made in its management. However, between 2011 and 2014 a number of pivotal developments were made that have improved the outlook for patients with IPF. Herein, we review this rapidly changing landscape, discussing key events whilst still acknowledging that IPF remains a challenging disease to diagnose and manage.http://err.ersjournals.com/content/24/135/65.full.pdf+html |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Ulrich Costabel |
| spellingShingle |
Ulrich Costabel The changing treatment landscape in idiopathic pulmonary fibrosis European Respiratory Review |
| author_facet |
Ulrich Costabel |
| author_sort |
Ulrich Costabel |
| title |
The changing treatment landscape in idiopathic pulmonary fibrosis |
| title_short |
The changing treatment landscape in idiopathic pulmonary fibrosis |
| title_full |
The changing treatment landscape in idiopathic pulmonary fibrosis |
| title_fullStr |
The changing treatment landscape in idiopathic pulmonary fibrosis |
| title_full_unstemmed |
The changing treatment landscape in idiopathic pulmonary fibrosis |
| title_sort |
changing treatment landscape in idiopathic pulmonary fibrosis |
| publisher |
European Respiratory Society |
| series |
European Respiratory Review |
| issn |
0905-9180 1600-0617 |
| publishDate |
2015-03-01 |
| description |
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and irreversible fibrotic disease of the lung that has greatly frustrated clinicians for a long time. The prognosis of IPF (median survival 2–5 years following diagnosis) is poorer than that of some cancers and for many years no significant advances were made in its management. However, between 2011 and 2014 a number of pivotal developments were made that have improved the outlook for patients with IPF. Herein, we review this rapidly changing landscape, discussing key events whilst still acknowledging that IPF remains a challenging disease to diagnose and manage. |
| url |
http://err.ersjournals.com/content/24/135/65.full.pdf+html |
| work_keys_str_mv |
AT ulrichcostabel thechangingtreatmentlandscapeinidiopathicpulmonaryfibrosis AT ulrichcostabel changingtreatmentlandscapeinidiopathicpulmonaryfibrosis |
| _version_ |
1724555266727346176 |